Meeting
2023 ASCO Annual Meeting
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
Authors
Sarina A. Piha-Paul
The University of Texas MD Anderson Cancer Center, Houston, TX
Sarina A. Piha-Paul , Sanjay Goel , Chih-Yi Liao , Nashat Y. Gabrail , Farshid Dayyani , Syed Mohammad Ali Kazmi , Yuan Yuan , Sayeh Moazami Lavasani , Jean Fan , Peng Peng , Caixia Sun , Hui Wang , Katie Hennessy , Ximei Fu , Shumao Ni , Hui Xian Tan , Brenda Ngo , Qinhua Cindy Ru , Frank Wu , Milind M. Javle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04742959
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3019)
DOI
10.1200/JCO.2023.41.16_suppl.3019
Abstract #
3019
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Early efficacy evaluation of ORIN1001, a first in class IRE1 alpha inhibitor, in advanced solid tumors.
First Author: Mothaffar F. Rimawi
First Author: Alison M. Schram
Poster
2024 ASCO Annual Meeting
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
First Author: Cristina Saura
Poster
2023 ASCO Annual Meeting
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
First Author: Timothy A. Yap